Through an assets sale transaction, Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX:ANP) has acquired all the research and development activities, manufacturing operations, key personnel, and intellectual property rights associated with Haemacure's human biomaterial product candidates.

Please direct any questions about Haemacure's product candidates or technology to Angiotech's Investor Relations department at 604-221-6933 or ir@angio.com.

More information regarding Angiotech can be found at www.angiotech.com.

Further to this transaction, Haemacure has ceased all activities.